https://www.selleckchem.com/pr....oducts/nazartinib-eg
008) at baseline than non-responders. Improvements in pain correlated with the baseline pain level (Pearson r= - 427, p 0.001). Structural joint changes such as tender, swollen, enlarged, or deformed joint counts did not differ between placebo responders and non-responders. In a multivariable analysis, only baseline AUSCAN pain was associated with a clinically meaningful placebo response (OR 1.054, 95% CI [1.019-1.089], p= 0.002). High levels of pain at baseline are predictive of a clinically meaningful placebo res
Like
Comment
Share
